BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/8/2026 11:12:35 AM | Browse: 7 | Download: 0
Publication Name World Journal of Cardiology
Manuscript ID 116558
Country China
Category Cardiac & Cardiovascular Systems
Manuscript Type Letter to the Editor
Article Title Ca2+/calmodulin-dependent protein kinase II in heart failure and the role of sodium-glucose-cotransporter 2 inhibitors
Manuscript Source Unsolicited Manuscript
All Author List Yi-Fei Zhang, Wu-Xiao Yang and Xue-Wen Li
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China No. 8217022047
Corresponding Author Xue-Wen Li, Chief Physician, PhD, Professor, Department of Cardiology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, No. 99 Longcheng Street, Taiyuan 030032, Shanxi Province, China. xuewenli1010@126.com
Key Words Sodium-glucose cotransporter 2 inhibitor; Heart failure; Ca2+/calmodulin-dependent protein kinase II; Oxidative stress; Calcium homeostasis
Core Tip Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have revolutionized the treatment of heart failure, but their direct molecular effects in cardiomyocytes, which express little sodium-glucose cotransporter-2, have not been fully described. This letter summarizes current evidence and presents a conceptual framework in which Ca2+/calmodulin-dependent protein kinase II is a central target. We hypothesize that many of the cardioprotective effects of SGLT2i are mediated by the dampening of Ca2+/calmodulin-dependent protein kinase II activity through synergistic modulation of ionic balance, relief of oxidative stress and inflammatory signaling suppression. Together, these processes may provide a unified explanation for the observed improvements in electrical stability, ventricular performance, and cardiac remodeling associated with SGLT2i treatment.
Citation Zhang YF, Yang WX, Li XW. Ca2+/calmodulin-dependent protein kinase II in heart failure and the role of sodium-glucose-cotransporter 2 inhibitors. World J Cardiol 2026; In press
Received
2025-11-14 11:40
Peer-Review Started
2025-11-17 00:36
First Decision by Editorial Office Director
2025-11-26 08:19
Return for Revision
2025-11-26 08:19
Revised
2025-12-04 16:34
Publication Fee Transferred
Second Decision by Editor
2026-01-08 02:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-01-08 11:12
Articles in Press
2026-01-08 11:12
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1949-8462 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com